Pholidota chinensis alleviates azoxymethane/dextran sulfate sodium-induced colorectal carcinogenesis through inhibition of TLR4 and COX-2
Background: Inflammatory bowel disease (IBD) always progresses to colorectal cancer (CRC) which is the second most frequent cause of death by cancer. It is about 2% of population in the lifetime worldwide who at the risk for development of CRC. Oxaliplatin is an effective anticancer drug used for the treatment of advanced CRC; however, it always causes a robust painful neuropathy. Pholidota chinensis is a Chinese folk herbal medicine which was used for treatment of inflammation such as gastroenteritis, duodenal ulcer and bronchitis.
Materials and Methods: The azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to induce the colon tumor of mice. The effect of Pholidota chinensis on colon tumorigenesis was evaluated. Immunohistochemistry and semi-quantitative RT-PCR were used to detect the expression of toll-like receptor 4 (TLR4) and cyclooxygenase-2 (COX-2) in colon.
Results: Pholidota chinensis can alleviate the colon tumorigenesis. The prevention effects of Pholidota chinensis are similar to oxaliplatin. Specifically, administration of Pholidota chinensis solution suppresses the expression of the proliferating cell nuclear antigen (PCNA), toll-like receptor 4 (TLR4) and cyclooxygenase-2 (COX-2).
Conclusion: Our findings suggested that Pholidota chinensis participate in the regulation of colon cancer development through inhibiting the expression of TLR4 and COX-2.
Keywords: Pholidota chinensis; colorectal cancer; Toll-like receptor 4; Cyclooxygenase-2
Copyright: Creative Commons Attribution CC.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.